HEP B AS A CASE STUDY
Use of hepatitis B in national immunization schemes

122 countries or 74% hepatitis B vaccine given to infants
12 countries or 7% use hepatitis B vaccine in part of the country or among adolescents
31 countries or 19% do not use hepatitis B vaccine

Project aim & lessons from Hep B

• Aim: to shorten the lag between vaccines being proven safe and effective for use in the industrial world, and their introduction into developing countries

• 15 years elapsed between development of vaccine and [near-] universal vaccination programmes
  – Required intervention of Task Force
    • Conducted demonstration programs to build global and national consensus for use of vaccine
  – Concentrated efforts of members to demonstrate the need for and feasibility of universal hepatitis B vaccination
  – Could not wait for WHO, EPI and UNICEF procedures. Supported by PATH

• Use was limited due to
  – Lack of awareness of disease burden
  – High price
Hep B Task Force Success

• Stimulated competition among manufacturers to reduce price
• Sealed bid and tender system to establish pricing procedure in Indonesia 1987
  – Seen as formality, expected few companies to compete
  – Lowest bid among many was a surprise. Cheil expected (PATH had negotiated transfer agreements). $0.95 from Korean Green Cross Company and willing to commit to provide vaccine to other public sector agencies
• Indonesian government adopted National Immunization program 1991
• Task Force defended scientific legitimacy of new Asian ‘cheap’ vaccines and convinced Western manufacturers to accept lower profits
Hep B Key Lessons 1

• Necessary to have a national ‘champion’,
  – Minister of Health in Indonesia 1984
• Culture not used to this type of entrepreneurship
  – Faced problems when addressing the possibility of local production, such as a belief that PATH was a private money-making organization
  – Involved a direct relationship with competitors
• Need to resolve conflict of interest with pharmaceuticals, and those representing both the Government and PATH (undermine local credibility)
• Careful choices required to transfer vaccine technology
  – Failed in Thailand, although success in adoption in to National Immunization program
Hep B Key Lessons 2

• Need to be aware of national politics and hierarchy
  – Role of PKK (woman’s movement) in Indonesia
  – Chinese movement towards private healthcare early 1990s restricted ‘effective market’ (Now China is cited by GAVI as ‘Success Story’ with accelerated immunization between 1999-2002)

• Need to be aware of national culture
  – Education materials poorly managed in Indonesia
  – Wasted money on booklets
  – Television more effective for raising awareness
  – Sri Lanka Ministry of Health placed amulet on poster
HEP B current situation

• Recombinant DNA vaccine now
• WHO recommends all infants receive hepatitis B vaccination
• Combination vaccine proven efficacious
  – but in Costa Rica, fewer than half of children returned for second dosage in trial
• Problems
  – GAVI Bridge Financing Proposals Phase I. Prices increased, lack of consensus on institutional responsibilities, lines of accountability, inaccurate demand forecasts
  – UNICEF lack of supplies of DTP3
LDC market tier pricing Hep B

India, 2001
Hep B vaccine price
$/dose

Brazil, 2000
Hep B vaccine price
$/dose

<table>
<thead>
<tr>
<th></th>
<th>GSK</th>
<th>Approximate public sector price</th>
<th>GSK, Merck*</th>
<th>ENILA (local distributor)</th>
<th>PAHO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$2</td>
<td></td>
<td>$5</td>
<td>$4</td>
<td>$0.58</td>
</tr>
</tbody>
</table>

* Price of GSK and Merck; private clinics may then mark up the price further.

Source: McKinsey India; McKinsey Brazil
PNEUMOCOCCAL CASE STUDY
Pneumococcal Conjugate Vaccine 2008

Source: WHO/IVB database, 193 WHO member States, Data as of June 2009
Coverage of 7 valent Pneumococcal Conjugate Vaccine

All regions except Asia >60% coverage; Asia 43%

Source: Hausdorff W. Clin Infect Dis 2001
Coverage of 11 valent Pneumococcal Conjugate Vaccine

All regions except Asia >85% coverage; Asia >70%

Source: Hausdorff W. Clin Infect Dis 2001
Pneumonia: Leading child killer

Pneumonia
• Mortality: ~25% of the 10M child deaths / yr
• Morbidity: ~151 million cases each year
  – 13-20 million are severe enough to require hospitalization

Pneumococcal disease
• Pneumococcus is the leading cause of child pneumonia deaths (~40%)
• About 1 in 10 child deaths due to pneumococcal disease
Nearly 70% of child pneumonia deaths occur in Africa & So. Asia

Projections based on Williams BG et al Lancet 2002
Each dot representing 1000 deaths
Prevention of pneumococcal disease is important

• HIV increases risk 20-40 times
• Antibiotic resistance complicates treatment
• Pneumococcal pneumonia follows pandemic influenza
  – Additional ~4.5M pneumococcal pneumonia cases and 450,000 deaths in children in GAVI countries
Prevenar: An interesting case study

Vaccine market

- Unicef/PAHO (5%)
- Adult Vaccine Market (15%)
- Pediatric Country Market (30%)
- Prevenar (10%)
- Proprietary Market (40%)

Prevenar Sales

- $461
- $800

Introduction
Prevenar: The first ‘blockbuster’ vaccine?

- Specifics about pneumo 90 serotypes, vary in impact around the world
- Capacity and IO issues
- Return to these issues below, since they mean that apparently simple policy solutions need to be much more subtle
- Others following this pattern
- MORE ON PNEUMOCOCCAL BELOW WHEN WE DISCUSS ROLE OF GAVI
Prevenar a big US success

“The vaccine is having a greater effect than anyone had imagined”
- Dr. Brendan Flannery, US CDC

Large herd immunity effect benefits the elderly

Routine vaccination in the United States is eliminating racial gap in pneumococcal disease...
Invasive Pneumococcal Disease in the USA, By Race, Children <5 years old, 1995 – 2002

Ref: Flannery B et al. JAMA 2004
Invasive Pneumococcal Disease in the USA, By Race, Children <5 years old, 1995 – 2002

Ref: Flannery B et al. JAMA 2004